Personalized Health Care (PHC) in Cancer - Genomic Biomarkers for Pharmaceutical Development - page 46

[72] Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, et al. Comparison of testing methods for the
detection of BRAF V600E mutations in malignant melanoma: Pre-approval validation study of the compan-
ion diagnostic test for vemurafenib. PLoS ONE 2013;8(1):e53733.
[73] Hoskins JM, McLeod HL. UGT1A and irinotecan toxicity: keeping it in the family. J Clin Oncol 2009;27(15):15
2419-21.
[74] Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M, et al. Genotype-directed, dose-inding
study of irinotecan in cancer patients with UGT1A1*28 and / orUGT1A1*6 polymorphisms. Cancer Sci
2011;102(10):1868-73.
[75] Marques SC, Ikediobi ON. The clinical application of UGT1A1 pharmacogenetic testing: gene-environment
interactions. Hum Genomics 2010;4(4):238-49.
[76] Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase
1A1 polymorphisms: are we there yet? Pharmacotherapy 2008;28:755-68.
[77] Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, et al. Characterization of the UDP glucuronosyl-
transferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab
Dispos 2007;35:2270-80.
[78] Stocco G, Crews KR, Evans. WE. Genetic polymorphism of inosinetriphosphate-pyrophosphatase inluences
mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized
for thiopurine-S-methyl-transferase status. Expert Opin Drug Saf 2010;9(1):23-37.
[79] Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RG, Krynetski EY, et al. Mercaptopurine ther-
apy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst
1999;91(23):2001-8.
[80] Yates CR, Krynetski EY, Loennechen T, Fessing MY, Tai HL, Pui CH, et al. Molecular diagnosis of thiopurine
S-methyltransferase deiciency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern
Med 1997;126(8):608-14.
[81] Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, et al. Genetic polymorphism of inosine
triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment
for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;85(2):164-72.
[82] Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Inluence of cytochrome P450 polymor-
phisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther
2007;116:496-526.
[83] Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2d6 ( CYP2D6 ): clinical consequences,
evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13.
[84] Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome p-450 mediated drug-
drug interactions: an update. Curr Drug Metab 2002;3:13-37.
[85] Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer
2009;9:576-86.
[86] Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, et al. Breast cancer treatment outcome
with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-93.
[87] Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamox-
ifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast
Cancer Res Treat 2005;91:249-58.
[88] Wegman P, Vainikka L, Stål O, Nordenskjöld B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes
and the beneit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-90.
[89] Wegman P, Elingarami S, Carstensen J, Stål O, Nordenskjöld B, Wingren S. Genetic variants of CYP3A5,
CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast
Cancer Res 2007;9:R7.
[90] Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. update of recommendations for the use of
tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
[91] Mroczkowski P, Schmidt U, Sahm M, Gastinger I, Lippert H, Kube R. Prognostic factors assessed for 15,096
patients with colon cancer in stages I and II. World J Surg 2012;36(7):1693-8.
[92] Albain KS, Paik S, van't Veer L. Prediction of adjuvant chemotherapy beneit in endocrine responsive, early
breast cancer using multigene assays. Breast 2009;18(Suppl. 3):S141-5.
[93] Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.